
NSPR Earnings
InspireMD Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of InspireMD Inc(NSPR) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of InspireMD Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
- | 2025-05-09 | Pre-Market | -0.17 | -0.22 | -29.41 | 1.40M | 1.53M | +9.21 | - | -8.85 |
FY2024Q4 | 2025-03-12 | Pre-Market | -0.20 | -0.19 | +5.00 | 1.82M | 1.95M | +7.29 | +0.72 | +0.36 |
- | 2024-08-06 | - | -0.19 | -0.22 | -15.79 | - | - | - | +0.68 | -4.05 |
- | 2024-05-14 | - | -0.15 | -0.21 | -40.00 | - | - | - | -0.83 | -5.00 |
FY2023Q4 | 2024-03-05 | - | -0.20 | -0.16 | +20.00 | 1.63M | 1.76M | +8.34 | +2.33 | -0.78 |
FY2023Q3 | 2023-11-06 | - | -0.17 | -0.15 | +11.76 | 1.50M | 1.56M | +3.87 | -3.19 | -8.99 |
- | 2023-08-08 | - | -0.17 | -0.24 | -41.18 | - | - | - | - | +1.29 |
- | 2021-03-09 | - | -0.06 | -0.10 | -66.67 | - | - | - | -3.80 | +16.46 |
NSPR Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, InspireMD Inc reported performance for , announced on 2025-05-09. The company achieved an EPS of -0.22, compared to analyst estimates of -0.17 by -29.41% . Revenue for the quarter reached 1.53M compared to expectations of 1.40M by 9.21% .
The stock price reacted with a 0.00% one-day change and a -8.85% five-day change following the earnings release. These movements reflect market reaction in InspireMD Inc growth trajectory and strategic initiatives.
NSPR Earnings Forecast
Looking ahead, InspireMD Inc(NSPR) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 1.52M and an EPS of -0.26.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 12.6%, while EPS estimates have been Revise Upward by 5.79%. For the upcoming Q2 2025, revenue estimates have been adjusted Revise Upward by 1.2% . These revisions correlate with a -3.94% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in InspireMD Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between NSPR's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward

+12.6%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+5.79%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward

+1.2%
In Past 3 Month
Stock Price
Go Down

-3.94%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:7.21M
--
EPS Estimate-Annual FY 2025:-1.00
—
Stock Price2.44
NSPR Revenue and EPS Performance: A Historical Perspective
InspireMD Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
(2025-05-09,Pre-Market):
EPS: -0.22 (Actual) vs.-0.17 (Estimate) (-29.41%)
Revenue: 1.53M (Actual) vs. 1.40M (Estimate) (9.21%)
Price Reaction: 0.00%(1-Day), -8.85%(5-Day)
FY2024Q4 (2025-03-12,Pre-Market):
EPS: -0.19 (Actual) vs.-0.20 (Estimate) (5.00%)
Revenue: 1.95M (Actual) vs. 1.82M (Estimate) (7.29%)
Price Reaction: 0.72%(1-Day), 0.36%(5-Day)
(2024-08-06,):
EPS: -0.22 (Actual) vs.-0.19 (Estimate) (-15.79%)
Revenue: 0.00 (Actual) vs. 0.00 (Estimate) (%)
Price Reaction: 0.68%(1-Day), -4.05%(5-Day)
Earnings Reaction
The chart below shows how NSPR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NSPR sees a +1.19% change in stock price 10 days leading up to the earnings, and a -3.83% change 10 days following the report. On the earnings day itself, the stock moves by -0.51%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -0.77% on the day following the earnings release and then changed by -2.69% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
InspireMD Inc (NSPR) Q1 2025 Earnings Call Summary
Negative
2025-05-10
The earnings call reveals several concerns: missed earnings expectations, increased operating expenses, and a significant net loss. The lack of forward-looking revenue guidance and the delay in FDA approval for CGuard Prime add to uncertainties. Despite positive clinical trial data and a strong sales force expansion, these factors, combined with competitive pressures and supply chain challenges, create a negative outlook. The absence of share repurchase or dividend programs further limits investor appeal. Overall, the sentiment is negative, with potential for a stock price decline in the range of -2% to -8%.
InspireMD Inc (NSPR) Q1 2025 Earnings Call Summary
Negative
2025-05-09
The earnings call highlights several concerns: increased net loss, rising operating expenses, and lack of revenue guidance. While there is optimism for FDA approval of CGuard Prime, delays and regulatory risks pose significant challenges. The financial health is strained with decreasing cash reserves. The Q&A session revealed vague responses about FDA interactions, raising uncertainty. Despite the potential for future growth and a shareholder return plan, immediate financial pressures and uncertainties weigh heavily, suggesting a negative stock price movement in the short term.
InspireMD Inc (NSPR) Q4 2024 Earnings Call Summary
Negative
2025-03-13
The earnings call reveals financial challenges, including increased costs and net losses, despite revenue growth. The Q&A highlights risks in US market entry and vague responses on operational expenses. The strategic plan's heavy reliance on FDA approval adds uncertainty. While revenue growth and strategic agreements are positive, the overall financial health and uncertain guidance lead to a negative sentiment.
InspireMD Inc (NSPR) Q4 2024 Earnings Call Summary
Negative
2025-03-12
The earnings call reveals several negative factors: increased net loss, declining gross margins, and rising operational costs. Despite revenue growth, the financial health appears strained. The lack of shareholder return plans and vague management responses in the Q&A add to concerns. Furthermore, the dependency on US market approval, which is uncertain, introduces significant risk. While there are growth opportunities, the current financial challenges and uncertainties outweigh the positives, leading to a negative sentiment overall.
InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Summary
Negative
2024-11-12
The earnings call reveals mixed signals: while there is positive growth in revenue and strategic agreements, the company faces significant regulatory risks, increased net loss, and operational expenses. The lack of a shareholder return plan and unclear management responses in the Q&A further dampen sentiment. Despite potential U.S. market entry and growth plans, financial challenges and competitive pressures in the market lead to a negative outlook for the stock price in the short term.
People Also Watch

XGN
Exagen Inc
8.450
USD
+14.34%

BNR
Burning Rock Biotech Ltd
5.810
USD
-15.80%

CLSD
Clearside Biomedical Inc
0.480
USD
+7.86%

LSF
Laird Superfood Inc
7.000
USD
-0.85%

PMVP
PMV Pharmaceuticals Inc
1.440
USD
-4.64%

AVTX
Avalo Therapeutics Inc
6.540
USD
-0.61%

OPTX
Syntec Optics Holdings Inc
1.890
USD
-10.00%

FUSB
First US Bancshares Inc
12.840
USD
-2.36%

LODE
Comstock Inc
3.330
USD
-3.48%
FAQ

What were the key highlights of NSPR’s latest earnings report for ?
NSPR reported its earnings on 2025-05-09, showcasing a revenue of 1.53M against an estimate of 1.40M, resulting in a 9.21% surprise. The EPS was -0.22, surpassing the expected -0.17 by -29.41% . The stock experienced a 0% price change on the earnings day and a -8.85% change over the next five days, reflecting market reactions to the results.

How did NSPR’s stock price react after the earnings release?

What are the revenue and EPS estimates for NSPR for 2025/Q2?

How does NSPR’s stock price correlate with earnings forecast revisions?

What should investors expect from NSPR’s next earnings report?
